IVERIC bio Inc (ISEE) Stock Overview
USA - NASDAQ:ISEE - US46583P1021 - Common Stock
ISEE Key Statistics, Chart & Performance
The current stock price of ISEE is 39.95 USD. In the past month the price increased by 4.55%. In the past year, price increased by 241.45%.
ISEE Latest News, Press Relases and Analysis
ISEE Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 21.46 | 401.56B | ||
| AMGN | AMGEN INC | 13.26 | 155.70B | ||
| GILD | GILEAD SCIENCES INC | 15.49 | 148.80B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.85 | 107.93B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.71 | 61.50B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 62.85B | ||
| ARGX | ARGENX SE - ADR | 90.06 | 51.07B | ||
| ONC | BEONE MEDICINES LTD-ADR | 5.09 | 34.61B | ||
| INSM | INSMED INC | N/A | 34.60B | ||
| NTRA | NATERA INC | N/A | 26.45B | ||
| BNTX | BIONTECH SE-ADR | N/A | 25.30B | ||
| BIIB | BIOGEN INC | 9.29 | 21.81B |
Related stock screener links
About ISEE
Company Profile
IVERIC bio, Inc. operates as a biopharmaceutical company. The company is headquartered in Parsippany, New Jersey and currently employs 74 full-time employees. The company went IPO on 2013-09-25. The firm is focused on the discovery and development of treatments for retinal diseases with unmet medical needs. Its lead asset is its clinical-stage product candidate, avacincaptad pegol, which is also referred to as ACP or Zimura, a complement C5 inhibitor. Zimura is targeting diseases including geographic atrophy (GA), intermediate age-related macular degeneration (AMD), and autosomal recessive Stargardt disease (STGD1). In addition to ACP, the Company is also developing its preclinical product candidate, IC-500, a high temperature requirement A serine peptidase 1 protein (HtrA1) inhibitor for GA secondary to AMD and potentially other age-related retinal diseases. Its portfolio also includes several ongoing gene therapy research programs, each of which uses adeno-associated virus (AAV) for gene delivery. These AAV mediated gene therapy programs are targeting the orphan inherited retinal diseases (IRDs).
Company Info
IVERIC bio Inc
8 Sylvan Way, Suite 2372
Parsippany NEW JERSEY 10001 US
CEO: Glenn P. Sblendorio
Employees: 74
Phone: 16094746755.0
IVERIC bio Inc / ISEE FAQ
What does IVERIC bio Inc do?
IVERIC bio, Inc. operates as a biopharmaceutical company. The company is headquartered in Parsippany, New Jersey and currently employs 74 full-time employees. The company went IPO on 2013-09-25. The firm is focused on the discovery and development of treatments for retinal diseases with unmet medical needs. Its lead asset is its clinical-stage product candidate, avacincaptad pegol, which is also referred to as ACP or Zimura, a complement C5 inhibitor. Zimura is targeting diseases including geographic atrophy (GA), intermediate age-related macular degeneration (AMD), and autosomal recessive Stargardt disease (STGD1). In addition to ACP, the Company is also developing its preclinical product candidate, IC-500, a high temperature requirement A serine peptidase 1 protein (HtrA1) inhibitor for GA secondary to AMD and potentially other age-related retinal diseases. Its portfolio also includes several ongoing gene therapy research programs, each of which uses adeno-associated virus (AAV) for gene delivery. These AAV mediated gene therapy programs are targeting the orphan inherited retinal diseases (IRDs).
What is the current price of ISEE stock?
The current stock price of ISEE is 39.95 USD. The price increased by 0.38% in the last trading session.
Does IVERIC bio Inc pay dividends?
ISEE does not pay a dividend.
How is the ChartMill rating for IVERIC bio Inc?
ISEE has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What do analysts say about IVERIC bio Inc (ISEE) stock?
14 analysts have analysed ISEE and the average price target is 39.88 USD. This implies a price decrease of -0.17% is expected in the next year compared to the current price of 39.95.
How is the valuation of IVERIC bio Inc (ISEE) based on its PE ratio?
IVERIC bio Inc (ISEE) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.76).
Can you provide the ownership details for ISEE stock?
You can find the ownership structure of IVERIC bio Inc (ISEE) on the Ownership tab.
ISEE Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to ISEE. When comparing the yearly performance of all stocks, ISEE is one of the better performing stocks in the market, outperforming 99.25% of all stocks.
ISEE Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ISEE. ISEE scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
ISEE Financial Highlights
Over the last trailing twelve months ISEE reported a non-GAAP Earnings per Share(EPS) of -1.76. The EPS decreased by -55.75% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | 0.2 |
ISEE Forecast & Estimates
14 analysts have analysed ISEE and the average price target is 39.88 USD. This implies a price decrease of -0.17% is expected in the next year compared to the current price of 39.95.